Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Pre-Mkt 06-25 08:29:26 EDT

3.83

+0.58

+17.85%

盘前3.63

-0.20-5.22%

08:29 EDT

High4.98	Low3.63	Vol8.58M
Open4.27	D1 Closing3.25	Amplitude41.54%
Mkt Cap7.69M	Tradable Cap6.30M	Total Shares2.01M
T/O38.41M	T/O Rate521.35%	Tradable Shares1.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":3.83,"timestamp":1782331200000,"preClose":3.25,"halted":0,"volume":8582407,"hourTrading":{"tag":"盘前","latestPrice":3.63,"preClose":3.83,"latestTime":"08:29 EDT","volume":21854,"amount":77698.63638319999,"timestamp":1782390543808,"change":-0.2,"changeRate":-0.052219,"amplitude":0.083551},"delay":0,"changeRate":0.17846153846153848,"floatShares":1646200,"shares":2008400,"eps":-10.427843,"marketStatus":"Pre-Mkt","change":0.58,"latestTime":"06-25 08:29:26 EDT","open":4.27,"high":4.98,"low":3.63,"amount":38413948.2880615,"amplitude":0.415385,"askPrice":3.64,"askSize":2,"bidPrice":3.55,"bidSize":901,"shortable":3,"etf":0,"ttmEps":-10.427843,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782394200000},"marketStatusCode":1,"adr":0,"adrRate":35,"exchange":"NASDAQ","adjPreClose":3.83,"preHourTrading":{"tag":"盘前","latestPrice":3.63,"preClose":3.83,"latestTime":"08:29 EDT","volume":21854,"amount":77698.63638319999,"timestamp":1782390543808,"change":-0.2,"changeRate":-0.052219,"amplitude":0.083551},"postHourTrading":{"tag":"盘后","latestPrice":3.7209,"preClose":3.83,"latestTime":"19:59 EDT","volume":120109,"amount":450767.9476,"timestamp":1782345586411,"change":-0.1091,"changeRate":-0.028486,"amplitude":0.073107},"volumeRatio":11.230630474474982},"requestUrl":"/m/hq/s/QNRX","defaultTab":"news","newsList":[{"id":"2645113816","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2645113816","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645113816?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:57","pubTimestamp":1782309457,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:57 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nAQN2M4ZSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645875837","title":"Quoin Pharmaceuticals Ltd : Maxim Group Cuts Target Price to $16 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2645875837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645875837?lang=en_us&edition=fundamental","pubTime":"2026-06-23 22:46","pubTimestamp":1782226016,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645983941","title":"Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2645983941","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645983941?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:58","pubTimestamp":1782219516,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals'  investigational candidate for the treatment of Netherton Syndrome has received US Food and Drug Administration conditional approval to use the brand name Qyleki for QRX003, the company said Tuesday.The FDA has also granted the drug fast track and rare pediatric disease designations, and a phase 3 study is expected to begin in H2 2026, the company said.Quoin expects to file a potential new drug application in 2027, the company said.Netherton Syndrome is a rare, inherited skin ailment caused by a gene mutation and can lead to severe skin dysfunctions.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645364248","title":"Quoin says FDA conditionally approves QYLEKI as brand name for QRX003 Netherton syndrome drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2645364248","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645364248?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:31","pubTimestamp":1782217919,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals secured FDA conditional clearance of QYLEKI as the proposed brand name for QRX003 in Netherton syndrome.The name will undergo final FDA proprietary review as part of a planned NDA filing targeted for 2027.Quoin expects to start a pivotal Phase 3 trial in the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL2MM0C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","NDAQ","LU0314104364.USD","IE00BKPKM429.USD","LU2210150020.SGD","QNRX","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644086923","title":"Quoin Pharmaceuticals Completes Establishment Of Japanese Subsidiary To Advance Commercial Readiness For Qrx003","url":"https://stock-news.laohu8.com/highlight/detail?id=2644086923","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644086923?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:07","pubTimestamp":1781788069,"startTime":"0","endTime":"0","summary":"June 18 (Reuters) - Quoin Pharmaceuticals Ltd <2EB0y.F>::*QUOIN PHARMACEUTICALS COMPLETES ESTABLISHMENT OF JAPANESE SUBSIDIARY TO ADVANCE COMMERCIAL READINESS FOR QRX003*QUOIN PHARMACEUTICALS - TO INI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nRSD7YHktZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644823085","title":"Quoin Pharmaceuticals establishes Japan subsidiary to support QRX003 commercialization plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2644823085","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644823085?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:31","pubTimestamp":1781785861,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals completed the establishment of a wholly owned subsidiary in Japan to support a planned direct launch of QRX003.Move strengthens commercial readiness in a core market following Japanese orphan-drug designation for QRX003 in Netherton syndrome.Japan subsidiary adds to a self-commercialization strategy in the US and Western Europe; partnerships cover 61 countries outside core territories.QRX003 is in Phase 2 whole-body trials; a pivotal Phase 3 study is slated for 2H 2026 with a potential NDA filing in 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL5cvBjH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD","BK4588","SG9999014013.SGD","IE00BKPKM429.USD","BK4139","SG9999014039.USD","BK4112","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","BK4585","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","QNRX","IE00B3QW5Z07.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643142750","title":"Quoin reports positive pediatric data in Netherton Syndrome program","url":"https://stock-news.laohu8.com/highlight/detail?id=2643142750","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643142750?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:18","pubTimestamp":1781615915,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced a positive clinical update from its ongoing pediatric Netherton Syndrome Compassionate Use program evaluatin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-reports-positive-pediatric-data-in-netherton-syndrome-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-reports-positive-pediatric-data-in-netherton-syndrome-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643275247","title":"Quoin says QRX003 improves 4 of 6 pediatric Netherton syndrome patients in compassionate use program","url":"https://stock-news.laohu8.com/highlight/detail?id=2643275247","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643275247?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:31","pubTimestamp":1781613104,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals reported a positive interim update from its pediatric compassionate-use program for QRX003 in Netherton syndrome.Most enrolled children were assessed as improved versus baseline across key clinical endpoints, supporting the drug’s potential in a core patient group.No treatment-related adverse events were reported in the cohort to date.A broader clinical data release, including results from ongoing Phase 2 studies, is scheduled for the coming months.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLSxMCJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4112","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4585","LU2210149790.SGD","BK4139","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643527577","title":"Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2643527577","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643527577?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:30","pubTimestamp":1781613000,"startTime":"0","endTime":"0","summary":"Four of Six Patients Participating in the Compassionate Use Program Were Classified as‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312590/0/en/Quoin-Pharmaceuticals-Announces-Positive-Clinical-Update-from-Ongoing-Pediatric-Netherton-Syndrome-Compassionate-Use-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139","IGA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615042","title":"Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615042","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640615042?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:03","pubTimestamp":1780578200,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals  said Thursday that Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to its experimental drug, QRX003, for the treatment of Netherton Syndrome.The company said the designation provides development incentives such as regulatory support, reduced fees, priority review, tax benefits, and up to 10 years of market exclusivity if approved.QRX003 is currently being evaluated in mid-stage studies, with a pivotal late-stage trial expected to begin in H2, Quoin said, adding that a US regulatory filing could follow next year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615745","title":"Quoin says Japan MHLW grants orphan drug status to QRX003 for Netherton syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615745","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640615745?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:32","pubTimestamp":1780576379,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals said Japan’s MHLW granted orphan drug designation for QRX003 to treat Netherton syndrome.Designation offers development incentives in Japan, including up to 10 years of market exclusivity on approval.Phase 3 trial expected to start in H2 2026; NDA filing targeted for 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7WzhZk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","SG9999014021.USD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD","LU2095319765.USD","QNRX","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","NDAQ","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640894906","title":"Quoin Pharmaceuticals submits QRX003 IND application to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640894906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640894906?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:36","pubTimestamp":1780410980,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced the submission of an investigational new drug, or IND, application to the FDA for QRX003 for the treatment o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-submits-qrx003-ind-application-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-submits-qrx003-ind-application-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","IND","QNRX","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640480899","title":"Quoin Pharmaceuticals submits FDA IND for QRX003 in Peeling Skin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2640480899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640480899?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:32","pubTimestamp":1780403571,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals submitted an FDA IND for QRX003 to treat Peeling Skin Syndrome, a rare disease with no approved therapy.FDA review is pending; a Phase 2 study is targeted for the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7Gx8gC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","NDAQ","LU0314104364.USD","IE00BKPKM429.USD","LU2210150020.SGD","QNRX","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634028468","title":"Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634028468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634028468?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:55","pubTimestamp":1778255718,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Naz Rahman reiterated a Buy rating on Quoin Pharmaceuticals yesterday and set a price target of $40.00. Rahman covers the Healt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/quoin-pharmaceuticals-qnrx-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/quoin-pharmaceuticals-qnrx-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633314243","title":"Quoin Pharmaceuticals Q1 EPS $(1.77) Misses $(1.72) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633314243","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633314243?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:32","pubTimestamp":1778157167,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.72) by 2.91 percent. This is a 72.77 percent increase over losses of $(6.50) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52364293/quoin-pharmaceuticals-q1-eps-1-77-misses-1-72-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914226","title":"Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914226","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914226?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:30","pubTimestamp":1778157000,"startTime":"0","endTime":"0","summary":"– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome  – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290007/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","ODD","BK4139","IE0009354923.USD","BK4183","LABU","BK4585","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633949173","title":"Quoin Pharmaceuticals Ltd  expected to post a loss of $1.93 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633949173","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633949173?lang=en_us&edition=fundamental","pubTime":"2026-05-05 22:33","pubTimestamp":1777991584,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd  expected to post a loss of $1.93 a share - Earnings Preview Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to  show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I27C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633957554","title":"Quoin Pharmaceuticals Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2633957554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633957554?lang=en_us&edition=fundamental","pubTime":"2026-05-05 01:13","pubTimestamp":1777914780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 13:13 ET (17:13 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932880","title":"Quoin Pharmaceuticals initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932880?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:11","pubTimestamp":1777889474,"startTime":"0","endTime":"0","summary":"Lucid Capital initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $30 price target Quoin is a late-stage clinical specialty ph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-initiated-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-initiated-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCIZ","BK4596","BK4139","BK4099","LCDL","QNRX","LCID","BK4551","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631163275","title":"Quoin Pharma to report Q1 results, provide corporate update May 7","url":"https://stock-news.laohu8.com/highlight/detail?id=2631163275","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631163275?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:33","pubTimestamp":1777552399,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals will release first-quarter 2026 financial results before market open on Thursday, May 7, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL53lGLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","QNRX","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014021.USD","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":-0.171},{"period":"1month","weight":-0.1971},{"period":"3month","weight":-0.4937},{"period":"6month","weight":-0.7262},{"period":"1year","weight":-0.5735},{"period":"ytd","weight":-0.7346}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0166},{"period":"3month","weight":0.1366},{"period":"6month","weight":0.0622},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0753}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.264124},{"month":2,"riseRate":0.2,"avgChangeRate":-0.199382},{"month":3,"riseRate":0.2,"avgChangeRate":-0.222445},{"month":4,"riseRate":0.2,"avgChangeRate":-0.15112},{"month":5,"riseRate":0.4,"avgChangeRate":-0.043514},{"month":6,"riseRate":0.4,"avgChangeRate":-0.10594},{"month":7,"riseRate":0.5,"avgChangeRate":-0.033987},{"month":8,"riseRate":0.5,"avgChangeRate":-0.098098},{"month":9,"riseRate":0,"avgChangeRate":-0.208503},{"month":10,"riseRate":0.5,"avgChangeRate":0.22434},{"month":11,"riseRate":0.4,"avgChangeRate":0.035616},{"month":12,"riseRate":0.2,"avgChangeRate":-0.187047}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals","securityTypeName":"DR","adrRate":"1:35"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}